Tuesday, August 27, 2013

Osmotica to compete with Alembic / Ranbaxy for a share in Desvenlafaxine base market

Alembic had expected they would be the sole player marketing a bioequivalent version of Pfizer's Pristiq until 2015. But to their surprise, recently Osmotica pharmaceuticals has also received an approval for selling a bioequivalent version of Pristiq. Osmotica would be selling it under the brand name Khedezla.

Enter your email address:


Delivered by FeedBurner